Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Announces Pre-Clinical Data Confirms Radio-Enhancing Potential of NOX66 for Paediatric Brain Cancer (DIPG)

• Diffuse Intrinsic Pontine Glioma (DIPG); highly aggressive and poorly responsive brain cancer of children

• Idronoxil (NOX66) significantly enhances ability of radiotherapy to kill DIPG cells.

Sydney, 5 July 2018: Noxopharm (ASX:NOX) today releases pre-clinical data providing important proof-of-concept of the ability of idronoxil (the active drug in NOX66) to increase the killing effect of radiation on brain cancer cells.

The data has been generated via a collaboration with the Children’s Cancer Institute (CCI) and is part of a broader program being conducted by Noxopharm into the use of idronoxil (as NOX66) as a radio-enhancer in the treatment of both primary and secondary brain cancers in adults and children. This particular collaboration with the CCI is looking at using NOX66 to enhance the ability of radiotherapy to treat diffuse intrinsic pontine glioma (DIPG), a highly aggressive and poorly responsive primary brain cancer of children.

For further information please download PDF attached:
Download this document